GLP-1 RAs can alleviate brain inflammation by inhibiting the activation and recruitment of glial cells both in vivo and in vitro following a variety of injury paradigms (7884)
Highlighting the delicate and complex balance required, inhibition of ROS has been shown to impair wound healing in numerous animal models 16,17,18,19,20,21,22,23 , whilst improvements in antioxidant capabilities have been shown to be beneficial in treatments of chronic and diabetic wounds 14,24,25
While promising for TB and respiratory infections, further evidence is required
This is especially useful for people with type 2 diabetes or insulin resistance
holds a significant share, driven by advanced reimbursement models, high awareness of metabolic disease management, and the rapid integration of GLP-1 therapies into standard care
Am J Clin Nutr 1981;34(8):1496-1500